{"transactions":[{"id":741725,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-06-11T20:05:11.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":77500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":77500,"derivative":{"exercise_price":6.61,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":77500},"source":{"system":"sec-edgar","filing":"0001193125-26-267494","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526267494/ownership.xml","form_type":"4"}},{"id":1092434,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-03T19:04:53.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28368,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation (\"Parent\"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the \"Company Common Stock\"), for a price per share of $4.00 (the \"Merger Consideration\"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option."}],"balance_after":0,"derivative":{"exercise_price":2.77,"expiration_date":"2030-05-27","underlying":"Common Stock","underlying_shares":28368},"source":{"system":"sec-edgar","filing":"0000950170-25-094093","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025094093/ownership.xml","form_type":"4"}},{"id":1111734,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-06-13T20:25:03.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":77500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 12, 2025 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":77500,"derivative":{"exercise_price":4.58,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":77500},"source":{"system":"sec-edgar","filing":"0000950170-25-086232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000095017025086232/ownership.xml","form_type":"4"}},{"id":1179430,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Head of Corp. Dev."}}],"security":"Common Stock, $0.0001 par value","published_at":"2025-04-03T16:16:04.000Z","date":"2025-04-02","kind":"sale","planned":false,"acquired":false,"shares":21867,"price":1.03,"value":22523.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading instruction to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes Restricted Stock Units which vest over time measured from the grant date."}],"balance_after":98905,"source":{"system":"sec-edgar","filing":"0000950170-25-050410","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000095017025050410/ownership.xml","form_type":"4"}},{"id":1187832,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Head of Corp. Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-31T16:16:03.000Z","date":"2025-03-28","kind":"grant","planned":false,"acquired":true,"shares":106000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On January 30, 2024, the Board of Directors granted the Reporting Person an option to purchase 106,000 shares of common stock. The underlying shares vest and become exercisable pursuant to the following schedule: one half of the shares subject to the option vest upon the  satisfaction of certain performance criteria, which were met on March 28, 2025, and the remaining shares subject to the option vest in 12 successive, equal monthly installments thereafter until fully vested, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":106000,"derivative":{"exercise_price":1.67,"expiration_date":"2035-03-27","underlying":"Common Stock","underlying_shares":106000},"source":{"system":"sec-edgar","filing":"0000950170-25-047746","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000095017025047746/ownership.xml","form_type":"4"}},{"id":1187831,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Head of Corp. Dev."}}],"security":"Common Stock, $0.0001 par value","published_at":"2025-03-31T16:16:03.000Z","date":"2025-03-28","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 30, 2024, the Board of Directors granted the Reporting Person 65,000 Restricted Stock Units (\"RSUs\") that vest in full upon the  satisfaction of certain performance criteria, which were met on March 28, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes RSUs that vest over time measured from the grant date."}],"balance_after":120772,"source":{"system":"sec-edgar","filing":"0000950170-25-047746","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000095017025047746/ownership.xml","form_type":"4"}},{"id":1281738,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Head of Corp. Dev."}}],"security":"Common Stock, $0.0001 par value","published_at":"2025-02-05T16:35:04.000Z","date":"2025-02-04","kind":"sale","planned":false,"acquired":false,"shares":153,"price":2.23,"value":341.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading instruction to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes Restricted Stock Units which vest over time measured from the grant date."}],"balance_after":55772,"source":{"system":"sec-edgar","filing":"0000950170-25-014570","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000095017025014570/ownership.xml","form_type":"4"}},{"id":1296305,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Head of Corp. Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-23T16:05:03.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares vest and become exercisable pursuant to the following schedule: one third of the shares subject to the option vest on December 31, 2025 and the remaining shares subject to the option vest in 24 successive, equal monthly installments thereafter on each monthly anniversary of December 31, 2025 until fully vested on December 31, 2027, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":150000,"derivative":{"exercise_price":2.09,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000950170-25-008315","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000095017025008315/ownership.xml","form_type":"4"}},{"id":1374153,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Head of Corp. Dev."}}],"security":"Common Stock, $0.0001 par value","published_at":"2024-11-06T16:10:04.000Z","date":"2024-11-04","kind":"sale","planned":false,"acquired":false,"shares":136,"price":1.29,"value":175.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading instruction to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes Restricted Stock Units which vest over time measured from the grant date."}],"balance_after":55925,"source":{"system":"sec-edgar","filing":"0000950170-24-122295","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000095017024122295/ownership.xml","form_type":"4"}},{"id":1439577,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Head of Corp. Dev."}}],"security":"Common Stock, $0.0001 par value","published_at":"2024-08-06T17:00:03.000Z","date":"2024-08-02","kind":"sale","planned":false,"acquired":false,"shares":139,"price":1.53,"value":212.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading instruction to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes Restricted Stock Units which vest over time measured from the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents adjusted total that includes an aggregate of 23,515 shares purchased under the Unity Biotechnology, Inc. 2018 Employee Stock Purchase Plan on May 15, 2023 and May 15, 2024 in transactions exempt from reporting pursuant to Rule 16b-3(c)."}],"balance_after":56061,"source":{"system":"sec-edgar","filing":"0000950170-24-091964","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000095017024091964/ownership.xml","form_type":"4"}},{"id":1468706,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Head of Corp. Dev."}}],"security":"Common Stock, $0.0001 par value","published_at":"2024-06-26T16:05:02.000Z","date":"2024-06-25","kind":"sale","planned":false,"acquired":false,"shares":324,"price":1.4,"value":453.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading instruction to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes Restricted Stock Units which vest over time measured from the grant date."}],"balance_after":32685,"source":{"system":"sec-edgar","filing":"0000950170-24-077848","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000095017024077848/ownership.xml","form_type":"4"}},{"id":1473206,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-20T16:12:40.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 18, 2024. The shares underlying the option are scheduled to vest as to 100% of the shares on June 18, 2025, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date."}],"balance_after":28000,"derivative":{"exercise_price":4.4,"expiration_date":"2034-06-17","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0000950170-24-075579","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017024075579/ownership.xml","form_type":"4"}},{"id":1480769,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-06-13T20:10:42.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":34400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 11, 2024 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":34400,"derivative":{"exercise_price":7.51,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":34400},"source":{"system":"sec-edgar","filing":"0000950170-24-073003","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000095017024073003/ownership.xml","form_type":"4"}},{"id":1854364,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-15T16:05:32.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 13, 2023. The shares underlying the option are scheduled to vest as to 100% of the shares on June 13, 2024,\nor, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date."}],"balance_after":16000,"derivative":{"exercise_price":6.18,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001209191-23-037301","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000120919123037301/doc4.xml","form_type":"4"}},{"id":1862424,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-06-09T01:21:07.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":9650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 6, 2023 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":9650,"derivative":{"exercise_price":6.37,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":9650},"source":{"system":"sec-edgar","filing":"0000899243-23-015004","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924323015004/doc4.xml","form_type":"4"}},{"id":1894983,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-12T20:09:22.000Z","date":"2023-05-11","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"On May 11, 2023, the option originally granted to the Reporting Person on February 9, 2022 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The underlying shares vest and become exercisable pursuant to the following schedule: One Third of the shares subject to the option vest on February 9, 2023 (the \"Vesting Commencement Date\"), and the remaining shares subject to the option vest in 24 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":20000,"derivative":{"exercise_price":2.77,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-23-012905","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924323012905/doc4.xml","form_type":"4"}},{"id":1894982,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-12T20:09:22.000Z","date":"2023-05-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"On May 11, 2023, the option originally granted to the Reporting Person on February 9, 2022 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The underlying shares vest and become exercisable pursuant to the following schedule: One Third of the shares subject to the option vest on February 9, 2023 (the \"Vesting Commencement Date\"), and the remaining shares subject to the option vest in 24 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":10.6,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-23-012905","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924323012905/doc4.xml","form_type":"4"}},{"id":1894981,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-12T20:09:22.000Z","date":"2023-05-11","kind":"grant","planned":false,"acquired":true,"shares":12333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On May 11, 2023, the option originally granted to the Reporting Person on June 24, 2021 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on June 24, 2021 (the \"Vesting Commencement Date\"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":12333,"derivative":{"exercise_price":2.77,"expiration_date":"2031-06-24","underlying":"Common Stock","underlying_shares":12333},"source":{"system":"sec-edgar","filing":"0000899243-23-012905","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924323012905/doc4.xml","form_type":"4"}},{"id":1894980,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-12T20:09:22.000Z","date":"2023-05-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On May 11, 2023, the option originally granted to the Reporting Person on June 24, 2021 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on June 24, 2021 (the \"Vesting Commencement Date\"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":41.8,"expiration_date":"2031-06-24","underlying":"Common Stock","underlying_shares":12333},"source":{"system":"sec-edgar","filing":"0000899243-23-012905","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924323012905/doc4.xml","form_type":"4"}},{"id":1894979,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-12T20:09:22.000Z","date":"2023-05-11","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On May 11, 2023, the option originally granted to the Reporting Person on August 1, 2020 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The underlying shares vest and become exercisable pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vested on August 1, 2021 (the \"Vesting Commencement Date\"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":24000,"derivative":{"exercise_price":2.77,"expiration_date":"2030-08-01","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0000899243-23-012905","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924323012905/doc4.xml","form_type":"4"}},{"id":1894978,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-12T20:09:22.000Z","date":"2023-05-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On May 11, 2023, the option originally granted to the Reporting Person on August 1, 2020 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The underlying shares vest and become exercisable pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vested on August 1, 2021 (the \"Vesting Commencement Date\"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":99.6,"expiration_date":"2030-08-01","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0000899243-23-012905","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924323012905/doc4.xml","form_type":"4"}},{"id":1894977,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-12T20:09:22.000Z","date":"2023-05-11","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":2.77,"value":110800.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares vest and become exercisable pursuant to the following schedule: One-eighth of the shares subject to the option vest in successive, equal quarterly installments starting on August 11, 2023, subject to the Reporting Person's continued service to Issuer through the applicable vesting date."}],"balance_after":40000,"derivative":{"exercise_price":2.77,"expiration_date":"2033-05-11","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-23-012905","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924323012905/doc4.xml","form_type":"4"}},{"id":1971269,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Options - Right to Buy","published_at":"2023-03-03T21:01:20.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":41000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 1, 2024, and the remainder vesting in 12 equal quarterly installments over three years."}],"balance_after":41000,"derivative":{"exercise_price":0.4,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0001213900-23-017212","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727640/000121390023017212/ownership.xml","form_type":"4"}},{"id":2085161,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2022-12-15T23:07:46.000Z","date":"2022-12-13","kind":"grant","acquired":true,"shares":9650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on December 13, 2022 and vests in full on the one-year anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":9650,"derivative":{"exercise_price":6.47,"expiration_date":"2032-12-13","underlying":"Common Stock","underlying_shares":9650},"source":{"system":"sec-edgar","filing":"0000899243-22-038682","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924322038682/doc4.xml","form_type":"4"}},{"id":2108505,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Head of Corp. Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2022-11-21T17:26:24.000Z","date":"2022-11-18","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The underlying shares vest and become exercisable pursuant to the following schedule: One-eighth of the shares subject to the option vest in successive, equal quarterly installments starting on February 18, 2023, subject to the Reporting Person's continued service to Issuer through the applicable vesting date."}],"balance_after":80000,"derivative":{"exercise_price":2.38,"expiration_date":"2032-11-18","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-22-036537","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924322036537/doc4.xml","form_type":"4"}},{"id":2108504,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Head of Corp. Dev."}}],"security":"Common Stock, $0.0001 par value","published_at":"2022-11-21T17:26:24.000Z","date":"2022-05-15","kind":"other","acquired":true,"shares":925,"price":6.89,"value":6373.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Unity Biotechnology, Inc. 2018 Employee Stock Purchase Plan (the ESPP). The acquisition of those 925 shares was also exempt pursuant to Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on May 15, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes RSUs which vest over time measured from the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Reflects a 1-for-10 reverse stock split of the Issuer's common stock,  effected by the Issuer on October 19, 2022, which was exempt from reporting pursuant to Rule 16a-9."}],"balance_after":33009,"source":{"system":"sec-edgar","filing":"0000899243-22-036537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924322036537/doc4.xml","form_type":"4"}},{"id":2232706,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-14T07:51:09.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":9367,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 10, 2022. The shares underlying the option are scheduled to vest as to 100% of the shares on June 10, 2023, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date."}],"balance_after":9367,"derivative":{"exercise_price":4.38,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":9367},"source":{"system":"sec-edgar","filing":"0001209191-22-036569","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000120919122036569/doc4.xml","form_type":"4"}},{"id":2237816,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2022-06-09T21:13:04.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":51000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 7, 2022 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":51000,"derivative":{"exercise_price":0.625,"expiration_date":"2032-06-07","underlying":"Common Stock","underlying_shares":51000},"source":{"system":"sec-edgar","filing":"0001209191-22-035465","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000120919122035465/doc4.xml","form_type":"4"}},{"id":2312442,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Options - Right to Buy","published_at":"2022-03-31T21:28:00.000Z","date":"2022-03-29","kind":"grant","acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 29, 2023, and the remainder vesting in 12 equal quarterly installments over three years."}],"balance_after":20500,"derivative":{"exercise_price":1.41,"expiration_date":"2032-03-29","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001213900-22-016980","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727640/000121390022016980/ownership.xml","form_type":"4"}},{"id":2394371,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Head of Corp. Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-15T17:17:53.000Z","date":"2022-02-09","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The underlying shares vest and become exercisable pursuant to the following schedule: One Third of the shares subject to the option vest on February 9, 2023 (the \"Vesting Commencement Date\"), and the remaining shares subject to the option vest in 24 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":200000,"derivative":{"exercise_price":1.06,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-22-006446","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924322006446/doc4.xml","form_type":"4"}},{"id":2394370,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Head of Corp. Dev."}}],"security":"Common Stock, $0.0001 par value","published_at":"2022-02-15T17:17:53.000Z","date":"2022-02-09","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") one third of which vests on February 9, 2023 with the remaining RSUs vesting in equal quarterly installments over a two year period thereafter. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes RSUs which vest over time measured from the grant date. Also includes 5,952 shares of Common Stock of the Issuer purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3."}],"balance_after":326785,"source":{"system":"sec-edgar","filing":"0000899243-22-006446","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924322006446/doc4.xml","form_type":"4"}},{"id":2620968,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrant","published_at":"2021-07-30T13:53:34.000Z","date":"2021-07-28","kind":"purchase","acquired":true,"shares":9375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The common stock warrant will be exercisable six months after the date of issuance, at an exercise price of $5.00 per share and will expire five years from the date such warrant first becomes exercisable."}],"balance_after":9375,"derivative":{"exercise_price":5,"exercise_date":"2022-01-28","expiration_date":"2027-01-28","underlying":"Common Stock","underlying_shares":9375},"source":{"system":"sec-edgar","filing":"0001213900-21-039439","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1727640/000121390021039439/ownership.xml","form_type":"4"}},{"id":2620967,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-30T13:53:34.000Z","date":"2021-07-28","kind":"purchase","acquired":true,"shares":12500,"price":4,"value":50000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of $4.00 per unit. The price paid per unit is reflected in Table I."}],"balance_after":12500,"source":{"system":"sec-edgar","filing":"0001213900-21-039439","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727640/000121390021039439/ownership.xml","form_type":"4"}},{"id":2653391,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Head of Corp. Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-28T17:17:20.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":123333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on June 24, 2021 (the \"Vesting Commencement Date\"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":123333,"derivative":{"exercise_price":4.18,"expiration_date":"2031-06-23","underlying":"Common Stock","underlying_shares":123333},"source":{"system":"sec-edgar","filing":"0000899243-21-026230","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924321026230/doc4.xml","form_type":"4"}},{"id":2653390,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Head of Corp. Dev."}}],"security":"Common Stock, $0.0001 par value","published_at":"2021-06-28T17:17:20.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":30833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") which vest in equal annual installments over a three year period measured from June 24, 2021.  Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes RSUs which vest over time measured from the grant date."}],"balance_after":270833,"source":{"system":"sec-edgar","filing":"0000899243-21-026230","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924321026230/doc4.xml","form_type":"4"}},{"id":2655878,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-24T16:14:52.000Z","date":"2021-06-23","kind":"grant","acquired":true,"shares":9367,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 23, 2021. The shares underlying the option are scheduled to vest as to 100% of the shares on June 23, 2022, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date."}],"balance_after":9367,"derivative":{"exercise_price":17.12,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":9367},"source":{"system":"sec-edgar","filing":"0001209191-21-043008","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000120919121043008/doc4.xml","form_type":"4"}},{"id":2661169,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-06-21T20:00:25.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 16, 2021 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":30000,"derivative":{"exercise_price":3.94,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-21-041939","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000120919121041939/doc4.xml","form_type":"4"}},{"id":2763306,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Options - Right to Buy","published_at":"2021-04-01T20:27:57.000Z","date":"2021-03-30","kind":"grant","acquired":true,"shares":15200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 30, 2022, and the remainder vesting in 12 equal quarterly installments over three years."}],"balance_after":15200,"derivative":{"exercise_price":7.02,"expiration_date":"2031-03-30","underlying":"Common Stock","underlying_shares":15200},"source":{"system":"sec-edgar","filing":"0001213900-21-019664","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727640/000121390021019664/ownership.xml","form_type":"4"}},{"id":3031278,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-09-15T21:10:19.000Z","date":"2020-09-13","kind":"grant","acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") one-third of which vests on September 13, 2021 with the remaining RSUs vesting in equal quarterly installments over a two year period thereafter.   Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") one-third of which vests on September 13, 2021 with the remaining RSUs vesting in equal quarterly installments over a two year period thereafter.   Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."}],"balance_after":240000,"source":{"system":"sec-edgar","filing":"0000899243-20-025187","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924320025187/doc4.xml","form_type":"4"}},{"id":3069529,"issuer":{"id":77428,"kind":"organization","name":"Unity Biotechnology, Inc.","symbol":"UBX"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option\n(Right to Buy)","published_at":"2020-08-04T18:12:40.000Z","date":"2020-08-01","kind":"grant","acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares vest and become exercisable pursuant to the following schedule:  Twenty Five  Percent (25%) of the shares subject to the option vested on August 1, 2021 (the \"Vesting Commencement Date\"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":240000,"derivative":{"exercise_price":9.96,"expiration_date":"2030-07-31","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0000899243-20-021189","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1463361/000089924320021189/doc4.xml","form_type":"4"}},{"id":3076257,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-07-24T16:43:48.000Z","date":"2020-07-23","kind":"grant","acquired":true,"shares":9367,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on July 23, 2020. The shares underlying the option are scheduled to vest as to 100% of the shares on July 23, 2021, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date."}],"balance_after":9367,"derivative":{"exercise_price":16,"expiration_date":"2030-07-22","underlying":"Common Stock","underlying_shares":9367},"source":{"system":"sec-edgar","filing":"0000899243-20-020390","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000089924320020390/doc4.xml","form_type":"4"}},{"id":3105624,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2020-06-18T20:23:39.000Z","date":"2020-06-16","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 16, 2020 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":30000,"derivative":{"exercise_price":3.03,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-20-037591","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000120919120037591/doc4.xml","form_type":"4"}},{"id":3120584,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-05T20:32:15.000Z","date":"2020-06-03","kind":"grant","acquired":true,"shares":14414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 3, 2020 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":14414,"derivative":{"exercise_price":2.23,"expiration_date":"2030-06-02","underlying":"Common Stock","underlying_shares":14414},"source":{"system":"sec-edgar","filing":"0000899243-20-015454","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000089924320015454/doc4.xml","form_type":"4"}},{"id":3192807,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Options - Right to Buy","published_at":"2020-03-27T20:00:40.000Z","date":"2020-03-25","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 25, 2021, and the remainder vesting in 12 equal quarterly installments over three years."}],"balance_after":16000,"derivative":{"exercise_price":6.21,"expiration_date":"2030-03-25","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001213900-20-007660","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1727640/000121390020007660/ownership.xml","form_type":"4"}},{"id":3489726,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2019-06-14T20:16:39.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 13, 2019 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":10000,"derivative":{"exercise_price":5.26,"expiration_date":"2029-06-13","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-037127","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000120919119037127/doc4.xml","form_type":"4"}},{"id":3533697,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-09T22:51:14.000Z","date":"2019-05-08","kind":"grant","acquired":true,"shares":14414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 8, 2019 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":14414,"derivative":{"exercise_price":7.99,"expiration_date":"2029-05-07","underlying":"Common Stock","underlying_shares":14414},"source":{"system":"sec-edgar","filing":"0000899243-19-012926","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000089924319012926/doc4.xml","form_type":"4"}},{"id":3729158,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2018-12-17T21:12:06.000Z","date":"2018-12-13","kind":"grant","acquired":true,"shares":8165,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on December 13, 2018 and vests in full on the earlier to occur of July 25, 2019 and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":8165,"derivative":{"exercise_price":23.58,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":8165},"source":{"system":"sec-edgar","filing":"0000899243-18-031211","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924318031211/doc4.xml","form_type":"4"}},{"id":3860966,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":39283,"kind":"person","name":"Sullivan Lynne Marie","position":1,"cik":"0001727640","reported_name":"Sullivan Lynne Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option\n(Right to Buy)","published_at":"2018-07-26T22:36:52.000Z","date":"2018-07-25","kind":"grant","acquired":true,"shares":1835,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on July 25, 2018 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events."}],"balance_after":1835,"derivative":{"exercise_price":37.89,"expiration_date":"2028-07-25","underlying":"Common Stock","underlying_shares":1835},"source":{"system":"sec-edgar","filing":"0000899243-18-020704","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924318020704/doc4.xml","form_type":"4"}}]}